Toxicity Management of Renal Cell Cancer Patients on Targeted Therapies
作者： Christian Kollmannsberger , G. A. Bjarnason , Alain Ravaud
DOI: 10.1007/978-3-319-17903-2_22
关键词: Vascular endothelial growth factor 、 Pazopanib 、 Temsirolimus 、 Medicine 、 Growth factor receptor 、 Axitinib 、 Sunitinib 、 Angiogenesis 、 Sorafenib 、 Cancer research
摘要: Targeted therapies have significantly changed the treatment landscape for patients with metastatic renal cell carcinoma (mRCC). TKIs such as sunitinib, sorafenib, pazopanib, and axitinib are all multi-targeted inhibitors which inhibit a variety of targets including vascular endothelial growth factor receptors 1, 2, 3, platelet-derived receptor (PDGFR), others. Temsirolimus everolimus both interfere angiogenesis by inhibiting mTOR, critical regulator within cell. Bevacizumab blocks (VEGF) pathway binding to VEGF.
springer.com
sci-hub.st 参考文章(110)
James C. Yang, Leah Haworth, Richard M. Sherry, Patrick Hwu, Douglas J. Schwartzentruber, Suzanne L. Topalian, Seth M. Steinberg, Helen X. Chen, Steven A. Rosenberg, A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer The New England Journal of Medicine. ,vol. 349, pp. 427- 434 ,(2003) , 10.1056/NEJMOA021491
P Wolter, C Stefan, B Decallonne, H Dumez, M Bex, P Carmeliet, P Schöffski, The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation British Journal of Cancer. ,vol. 99, pp. 448- 454 ,(2008) , 10.1038/SJ.BJC.6604497
S. Lee, H.C. Chung, P. Mainwaring, C. Ng, J.W.C. Chang, P. Kwong, R.K. Li, V. Sriuranpong, C.K. Toh, S. Pitman Lowenthal, 7118 An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma Ejc Supplements. ,vol. 7, pp. 428- ,(2009) , 10.1016/S1359-6349(09)71451-X
CF Xu, BH Reck, Z Xue, L Huang, KL Baker, M Chen, EP Chen, HE Ellens, VE Mooser, LR Cardon, CF Spraggs, L Pandite, None, Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism British Journal of Cancer. ,vol. 102, pp. 1371- 1377 ,(2010) , 10.1038/SJ.BJC.6605653
Elaine Wong, Lee S. Rosen, Marilyn Mulay, Andy VanVugt, Melissa Dinolfo, Chisato Tomoda, Masahiro Sugawara, Jerome M. Hershman, Sunitinib induces hypothyroidism in advanced cancer patients and may inhibit thyroid peroxidase activity. Thyroid. ,vol. 17, pp. 351- 355 ,(2007) , 10.1089/THY.2006.0308
Rashmi R. Shah, Joel Morganroth, Devron R. Shah, Hepatotoxicity of Tyrosine Kinase Inhibitors: Clinical and Regulatory Perspectives Drug Safety. ,vol. 36, pp. 491- 503 ,(2013) , 10.1007/S40264-013-0048-4
Thomas Force, Kyle L. Kolaja, Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes Nature Reviews Drug Discovery. ,vol. 10, pp. 111- 126 ,(2011) , 10.1038/NRD3252
Eric W Mueller, Michelle L Rockey, Mitchell C Rashkin, Sunitinib-related Fulminant Hepatic Failure: Case Report and Review of the Literature Pharmacotherapy. ,vol. 28, pp. 1066- 1070 ,(2008) , 10.1592/PHCO.28.8.1066
C. Porta, C. Paglino, I. Imarisio, L. Bonomi, Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clinical and Experimental Medicine. ,vol. 7, pp. 127- 134 ,(2007) , 10.1007/S10238-007-0145-8
Kun-Ying Tsai, Chih-Hsun Yang, Tseng-tong Kuo, Hong-Shang Hong, John W.C. Chang, Hand-Foot Syndrome and Seborrheic Dermatitis-Like Rash Induced by Sunitinib in a Patient With Advanced Renal Cell Carcinoma Journal of Clinical Oncology. ,vol. 24, pp. 5786- 5788 ,(2006) , 10.1200/JCO.2006.08.6868